Abstract library

6 results for "Malik".
#412 Single Institutional Series of Neuroendocrine Tumors Managed in the Australian Capital Territory
Introduction: Neuroendocrine tumors (NETs) have been regarded as indolent tumors with significantly variable clinical behavior. Limited information is available on long-term clinical outcome and clinically applicable prognostic factors.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Laeeq Malik
Authors: Malik L, Chua Y, Yip D, Butt N
#1757 Therapeutic Strategies in Patients with Neuroendocrine Neoplasm: 30 Month Follow-Up pf Long Survivors from EPH Mostaganem and EHU Oran Medical Oncology
Introduction: Neuro docrine tumors are poorly known and infrequent tumors are, most of the time, diagnosed late, often occurring between the age of 40 and 60.They mainly appear in the gastro intestinal system, pancreas, bronchi, lungs, thymus and thyroid.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Aicha Bengueddach
#1921 Prognostic Factors That Mandate Long Term Follow Up Following Surgery for Appendiceal Neuroendocrine Tumours (aNETs)
Introduction: Appendiceal neuroendocrine tumours (aNETs) are usually diagnosed incidentally at appendicectomy and rarely recur. Current ENET guidelines inform their management and highlight areas of uncertainty.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Edward Alabraba
Authors: Alabraba E, Banks M, Malik H, Fenwick S, ...
Keywords: Appendix NET
#2076 Pancreatic Neuroendocrine Tumor in Polish Population with MEN 1 Syndrome
Introduction: The multiple endocrine neoplasia type 1 (MEN 1) is a genetically conditioned syndrome which is characterised by usually mild parathyroid and pituary gland adenomas, pancreatic neuroendocrine tumor (pNET). The last appear in 30-70% of MEN 1 patients being main life-threatening manifstation among MEN 1 patients. The prognosis might improve by presymptomatic tumor detection.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: MD Przemysław Soczomski
#2870 When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites
Introduction: Histological diagnostic of neuroendocrine neoplasms (NEN) relies on morphological criteria and expression of several neuroendocrine marker assessed by immunohistochemistry. Systematic large evaluation of classical (chromogranin A (chrA), synaptophysin (Syn), CD56) and emerging (chromogranin B (chrB), INSM1) markers are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Dr Jerome Cros
Authors: Mamodaly M, Chen R, Cazes A, Guedj N, ...
#3055 Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours
Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Daria Handkiewicz-Junak
Keywords: CgA, PRRT, prognosis